AstraZeneca to Invest $1B for the Transformation of Healthcare in China

Share this

AstraZeneca to Invest $1B for the Transformation of Healthcare in China


  • AstraZeneca takes three large-scale initiatives which include the formation of new Global R&D Centre and an AI Innovation Centre- both in Shanghai and collaborate with CICC to jointly formed the Healthcare Industrial Fund for the transformation of healthcare in China
  • Initially- AstraZeneca funded $1B to the Health Care Fund supporting the domestic companies- the R&D Centre to focus on the disease prevalent in China and AI innovation Centre is to utilize digital technology in R&D- manufacturing- operations and commercialization to accelerate the delivery of therapies in China and across the globe
  • AstraZeneca signed MoU with the Shanghai Jing'an District People's Government at the CIIE for the creation of R&D and AI Centres and a separate agreement with CICC for the joint investment fund. Additionally- AstraZeneca signed a license agreement with Sun Pharma for novel ready-to-use (RTU) infusion oncology therapies in China

Click here to­ read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions